PARP2: A Potential Drug Target and Biomarker (G10038)

Target Name: PARP2

NCBI ID: G10038

PARP2

PARP2: A Potential Drug Target and Biomarker

Parathyroid hormone (PTH) is a hormone produced by the parathyroid gland that regulates the levels of calcium in the body. It is essential for maintaining strong bones and maintaining the proper functioning of various bodily systems. However, in some individuals, the levels of PTH produced by the parathyroid gland may be too high or too low, leading to the development of a condition known as hyperparathyroidism. This condition can cause a range of symptoms, including increased thirst, decreased urine, and muscle weakness.

One potential drug target for hyperparathyroidism is PARP2, a protein that is expressed in the parathyroid gland. PARP2 is a transcription factor that is responsible for regulating the expression of genes in the parathyroid gland. It has been shown to play a role in the regulation of PTH levels and may be a useful target for the treatment of hyperparathyroidism.

Research has suggested that individuals with hyperparathyroidism may have increased levels of PARP2 in their parathyroid gland. This may be because the parathyroid gland is trying to compensate for an overactive thyroid gland, which produces too much thyroid hormone. By inhibiting the activity of PARP2, researchers may be able to reduce the production of PTH and alleviate the symptoms of hyperparathyroidism.

In addition to its potential use as a drug target, PARP2 has also been identified as a potential biomarker for hyperparathyroidism. Studies have shown that individuals with hyperparathyroidism may have increased levels of PARP2 in their bloodstream. This may be because the increased production of PTH leads to an increase in the production of other proteins, including PARP2.

While further research is needed to fully understand the role of PARP2 in the treatment of hyperparathyroidism, it is an promising target for future research. If proven to be effective, a drug that targets PARP2 may be a valuable new treatment option for individuals with this condition.

Protein Name: Poly(ADP-ribose) Polymerase 2

Functions: Poly-ADP-ribosyltransferase that mediates poly-ADP-ribosylation of proteins and plays a key role in DNA repair (PubMed:10364231, PubMed:25043379, PubMed:27471034, PubMed:30104678, PubMed:32028527, PubMed:32939087, PubMed:34486521, PubMed:34874266, PubMed:34108479). Mediates glutamate, aspartate or serine ADP-ribosylation of proteins: the ADP-D-ribosyl group of NAD(+) is transferred to the acceptor carboxyl group of target residues and further ADP-ribosyl groups are transferred to the 2'-position of the terminal adenosine moiety, building up a polymer with an average chain length of 20-30 units (PubMed:25043379, PubMed:30104678, PubMed:30321391). Serine ADP-ribosylation of proteins constitutes the primary form of ADP-ribosylation of proteins in response to DNA damage (PubMed:32939087). Mediates glutamate and aspartate ADP-ribosylation of target proteins in absence of HPF1 (PubMed:25043379). Following interaction with HPF1, catalyzes serine ADP-ribosylation of target proteins; HPF1 conferring serine specificity by completing the PARP2 active site (PubMed:28190768, PubMed:32028527, PubMed:34486521, PubMed:34874266, PubMed:34108479). PARP2 initiates the repair of double-strand DNA breaks: recognizes and binds DNA breaks within chromatin and recruits HPF1, licensing serine ADP-ribosylation of target proteins, such as histones, thereby promoting decompaction of chromatin and the recruitment of repair factors leading to the reparation of DNA strand breaks (PubMed:10364231, PubMed:32939087, PubMed:34108479). HPF1 initiates serine ADP-ribosylation but restricts the polymerase activity of PARP2 in order to limit the length of poly-ADP-ribose chains (PubMed:34732825, PubMed:34795260). Specifically mediates formation of branched poly-ADP-ribosylation (PubMed:30104678). Branched poly-ADP-ribose chains are specifically recognized by some factors, such as APLF (PubMed:30104678). In addition to proteins, also able to ADP-ribosylate DNA: preferentially acts on 5'-terminal phosphates at DNA strand breaks termini in nicked duplex (PubMed:27471034, PubMed:29361132)

The "PARP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PARP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets